Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.
about
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Recent developments in immunotherapy of acute myeloid leukemia.Acute myeloid leukemia in the elderly: therapeutic options and choice.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.Dendritic Cell Therapies for Hematologic Malignancies.Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.Towards personalized, tumour-specific, therapeutic vaccines for cancer.Advances in immunotherapy for pediatric acute myeloid leukemia.MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.Latest developments in MUC1 immunotherapy.The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer CareEndometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
P2860
Q33892358-4F0668F2-EE54-4858-B99D-1668A5E6BD7EQ38661895-2EE93227-B742-49DC-90F2-3FFA94063D04Q38675781-03333DCC-249D-4808-8F56-7D99AC863E32Q39243052-CEB7FA28-3816-4911-A55A-65F1E97E2DE8Q39243064-33A6F348-6A92-4BD0-907D-0B4565F85F20Q39289930-CD29D6F6-CE33-494A-9403-316154357D0AQ43297784-09462B77-D49B-476F-BC31-759380C60B49Q47146837-28D0681F-120D-44ED-900A-398BAFF2CD19Q47789519-F35E5567-91AF-4D74-B608-B26CD6405148Q47930962-68FBE302-BC53-41DC-94FB-4998A8A9A6D9Q48146766-0C508107-1D21-4932-840F-93611350872BQ49835172-17E7FABF-76A6-457D-9CD3-0F6EB75E9345Q52716912-237D3619-5FC3-4732-BDEB-EC65101A25ADQ55174561-393C6BC1-8EB5-432D-BAA5-CECB572AF866Q55299267-2CC9BCED-F9FF-478C-8C50-87838129566CQ55397325-5511C1CA-4A0E-4F44-B366-D3DCB9FABF63Q55417304-09793F8E-ECC5-4E0F-96B7-4B44AF249996Q58697933-8517EE92-00BA-42EE-AA60-1BB82491FDEDQ58702694-84895C92-DBB0-4269-8DAE-64E86DC8A00B
P2860
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Individualized vaccination of ...... nity and prolonged remissions.
@en
Individualized vaccination of ...... nity and prolonged remissions.
@nl
type
label
Individualized vaccination of ...... nity and prolonged remissions.
@en
Individualized vaccination of ...... nity and prolonged remissions.
@nl
prefLabel
Individualized vaccination of ...... nity and prolonged remissions.
@en
Individualized vaccination of ...... nity and prolonged remissions.
@nl
P2093
P2860
P1476
Individualized vaccination of ...... nity and prolonged remissions.
@en
P2093
Abigail Washington
Ayad Hamdan
Daniel J DeAngelo
David Avigan
David P Steensma
Dina Stroopinsky
Donald Kufe
Donna Neuberg
Emma Logan
Ilene Galinsky
P2860
P304
P356
10.1126/SCITRANSLMED.AAG1298
P407
P577
2016-12-01T00:00:00Z